Mylan Company Profile (NASDAQ:MYL)

About Mylan

Mylan logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MYL
  • CUSIP: 62853010
Key Metrics:
  • Previous Close: $43.22
  • 50 Day Moving Average: $46.82
  • 200 Day Moving Average: $45.34
  • Trailing P/E Ratio: 27.35
  • Foreward P/E Ratio: 7.44
  • P/E Growth: 0.60
  • Market Cap: $23.12B
  • Outstanding Shares: 534,911,000
  • Beta: 1.25
Additional Links:
Companies Related to Mylan:

Analyst Ratings

Consensus Ratings for Mylan (NASDAQ:MYL) (?)
Ratings Breakdown: 8 Hold Ratings, 6 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.53)
Consensus Price Target: $55.92 (29.39% upside)

Analysts' Ratings History for Mylan (NASDAQ:MYL)
DateFirmActionRatingPrice TargetDetails
8/26/2016Evercore ISIReiterated RatingHold$49.00View Rating Details
8/25/2016Goldman Sachs Group Inc.Reiterated RatingConviction-Buy$60.00View Rating Details
8/25/2016Wells Fargo & Co.Reiterated RatingMarket Perform$44.00View Rating Details
8/24/2016Bank of America Corp.Reiterated RatingBuy$70.00View Rating Details
8/15/2016Leerink SwannBoost Price TargetOutperform$51.00 -> $55.00View Rating Details
7/12/2016Morgan StanleyReiterated RatingHoldView Rating Details
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
3/8/2016BTIG ResearchReiterated RatingBuy$60.00View Rating Details
2/19/2016ArgusLower Price TargetBuy$65.00 -> $55.00View Rating Details
2/11/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
2/11/2016GuggenheimReiterated RatingNeutralView Rating Details
2/11/2016Royal Bank Of CanadaReiterated RatingHold$60.00 -> $58.00View Rating Details
2/11/2016Cowen and CompanyLower Price TargetMarket Perform$65.00 -> $55.00View Rating Details
11/16/2015BMO Capital MarketsLower Price TargetMarket Perform$46.00View Rating Details
9/21/2015Barclays PLCInitiated CoverageEqual Weight$57.00View Rating Details
8/26/2015Standpoint ResearchInitiated CoverageBuy$70.00View Rating Details
8/12/2015SusquehannaLower Price TargetPositive$85.00 -> $68.00View Rating Details
8/7/2015Deutsche Bank AGReiterated RatingBuy$65.00 -> $66.00View Rating Details
8/7/2015Sanford C. BernsteinLower Price Target$83.00 -> $60.00View Rating Details
6/18/2015B. RileyInitiated CoverageBuy$85.00 -> $71.23View Rating Details
6/3/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
4/22/2015CRT CapitalBoost Price TargetBuy$68.00 -> $87.00View Rating Details
10/6/2014S&P Equity ResearchReiterated RatingBuyView Rating Details
10/6/2014ING GroupReiterated RatingBuy$68.00View Rating Details
(Data available from 8/30/2014 forward)


Earnings History for Mylan (NASDAQ:MYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.69$0.70$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.73$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.68$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mylan (NASDAQ:MYL)
Current Year EPS Consensus Estimate: $4.97 EPS
Next Year EPS Consensus Estimate: $5.81 EPS


Dividend History for Mylan (NASDAQ:MYL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Mylan (NASDAQ:MYL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Mylan (NASDAQ:MYL)
News IconMylan to Launch Cheaper Generic Version of EpiPen (NASDAQ:MYL) - August 29 at 6:09 PM
News IconMylan Launching Generic $300 Version Of EpiPen (NASDAQ:MYL) - August 29 at 6:09 PM logoMylan’s Lower-Cost EpiPen May Not Hurt Drugmaker’s Sales Much (NASDAQ:MYL) - August 29 at 6:09 PM logoMylan to launch generic EpiPen at half the price of original (NASDAQ:MYL) - August 29 at 6:09 PM
News IconMylan to produce "generic" version of EpiPen (NASDAQ:MYL) - August 29 at 10:51 AM
News IconMylan launching generic version of EpiPen (NASDAQ:MYL) - August 29 at 10:51 AM logoMylan plans generic EpiPen (NASDAQ:MYL) - August 29 at 10:51 AM
News IconThe Mylan EpiPen Debacle: How Tremendous Greed Can Lead to the Demise of a Leader (NASDAQ:MYL) - August 29 at 10:51 AM logoMylan Will Launch First Generic EpiPen At Half The Price (NASDAQ:MYL) - August 29 at 10:51 AM logoMylan To Launch Its Own EpiGen Generic Rival At Half Price (NASDAQ:MYL) - August 29 at 10:51 AM logoMylan NV (MYL) Will Launch Generic EpiPens (NASDAQ:MYL) - August 29 at 10:18 AM logoUPDATE 1-Mylan to launch first generic to EpiPen allergy injection (NASDAQ:MYL) - August 29 at 7:25 AM logoThe maker of EpiPens says it gives thousands to schools for free – and may get huge tax breaks in the process (NASDAQ:MYL) - August 28 at 5:40 PM logoPharma Companies Are Spending Millions To Sustain High Drug Prices (NASDAQ:MYL) - August 28 at 1:00 PM logoThe EpiPen Lies - Seeking Alpha (NASDAQ:MYL) - August 28 at 10:27 AM logo3 Companies That Destroyed Shareholders Last Week (NASDAQ:MYL) - August 28 at 10:27 AM
News IconRalph Nader on EpiPen Price Controversy: 'Greed on Steroids' (NASDAQ:MYL) - August 27 at 5:45 PM
News IconThe EpiPen Scandal Is Worse Than You Think: What You’re Not Being Told (NASDAQ:MYL) - August 27 at 5:45 PM
News IconEpiPen maker’s stock value plunges nearly $3 billion as investors panic (NASDAQ:MYL) - August 27 at 10:40 AM logoCritics want more from Mylan over EpiPens (NASDAQ:MYL) - August 27 at 10:40 AM logoSenators Probing EpiPen Received Donations From Mylan PAC (NASDAQ:MYL) - August 27 at 10:40 AM logoMylan Ups EpiPen Price, Banks Maintain “Buy” Ratings (NASDAQ:MYL) - August 27 at 10:40 AM
News IconGovernment Funds to Mylan Spiked After Manchin’s Daughter Became CEO (NASDAQ:MYL) - August 27 at 10:40 AM logoThe EpiPen pricing surge scandal brings out the worst parts of our government and healthcare system (NASDAQ:MYL) - August 27 at 10:40 AM
News IconThe makers of the EpiPen just made a move to try and put an end to growing fury over the drug's price (NASDAQ:MYL) - August 26 at 6:05 PM logoMylan Reacts to EpiPen Backlash (NASDAQ:MYL) - August 26 at 6:05 PM logoMylan NV (MYL) to Reduce EpiPen Price Amid Outcry (NASDAQ:MYL) - August 26 at 6:05 PM logoSen. Joe Manchin, Father of Mylan’s CEO, Airs ‘Concerns’ About Drug Costs (NASDAQ:MYL) - August 26 at 6:05 PM logoPharma Has History of Price Gouging, Mylan Should Be No Surprise (NASDAQ:MYL) - August 26 at 6:05 PM logoWe need something more sweeping than Dodd-Frank for pharma, Howard Dean says (NASDAQ:MYL) - August 26 at 6:04 PM logoMylan Is Offering An EpiPen Savings Card, But A Lot Of People Will Still Get Screwed (NASDAQ:MYL) - August 26 at 4:25 PM logoTrend In EpiPen's Climbing Prices Mirror Product's Social Media Mentions - Benzinga (NASDAQ:MYL) - August 26 at 9:24 AM logoWhat's Going On At Mylan? - Seeking Alpha (NASDAQ:MYL) - August 26 at 9:24 AM logoUPDATE 6-Mylan offers discounts on EpiPen amid wave of criticism (NASDAQ:MYL) - August 25 at 6:57 PM logoWill Mylan Inc. (NASDAQ:MYL) Surprise Analysts? - Investor Newswire (NASDAQ:MYL) - August 25 at 6:19 PM logoStocks end at 2-week low as drop in Mylan shares punishes health ... - MarketWatch (NASDAQ:MYL) - August 25 at 6:19 PM logoMylan Cuts EpiPen Costs By Up To 50% Via Coupon - Benzinga (NASDAQ:MYL) - August 25 at 6:19 PM logoShocked! Mylan, Biotechs Swoon After Hillary's Statement - Seeking Alpha (NASDAQ:MYL) - August 25 at 6:19 PM logoAfter backlash, EpiPen maker to help reduce patient costs (NASDAQ:MYL) - August 25 at 6:19 PM logoMylan 'Took The Sting' Out Of The EpiPen Controversy (NASDAQ:MYL) - August 25 at 3:30 PM logoMylan (MYL) to Reduce EpiPen Price After Backlash (NASDAQ:MYL) - August 25 at 11:34 AM
News IconUPDATE: Stocks end at 2-week low as drop in Mylan shares punishes health care (NASDAQ:MYL) - August 25 at 11:27 AM logoMylan says it'll cover more out-of-pocket costs of EpiPen (NASDAQ:MYL) - August 25 at 11:27 AM logoMylan to Reduce EpiPen Costs as Political Pressure Mounts (NASDAQ:MYL) - August 25 at 11:27 AM
News IconMylan boosts EpiPen patient programs, doesn't budge on price (NASDAQ:MYL) - August 25 at 11:27 AM logoMylan Faces Scrutiny Over EpiPen Price Increases (NASDAQ:MYL) - August 25 at 11:27 AM logoMylan Is Done Leaning on EpiPen Sales and That Could be a Big Problem (NASDAQ:MYL) - August 25 at 11:27 AM logoThe maker of the EpiPen is playing a dirty trick right from Martin Shkreli's book (NASDAQ:MYL) - August 25 at 11:27 AM logoCramer on Mylan CEO: 'Whatever you can get away with' (NASDAQ:MYL) - August 25 at 11:27 AM logoHow Mylan's EpiPen Fight Could Sting Investors (NASDAQ:MYL) - August 25 at 11:27 AM


Mylan (NASDAQ:MYL) Chart for Tuesday, August, 30, 2016

Last Updated on 8/30/2016 by Staff